[{"address1": "The MediaWorks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 399, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 2151685, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 50, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 57, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 66, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 56, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edgar E. W. Braendle M.D., Ph.D.", "age": 62, "title": "Senior VP & Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 42, "title": "Senior Vice President of Corporate Development", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "title": "Chief Human Resources Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.54, "open": 6.63, "dayLow": 6.34, "dayHigh": 6.94, "regularMarketPreviousClose": 6.54, "regularMarketOpen": 6.63, "regularMarketDayLow": 6.34, "regularMarketDayHigh": 6.94, "payoutRatio": 0.0, "beta": 1.567, "forwardPE": -7.62069, "volume": 1978735, "regularMarketVolume": 1978735, "averageVolume": 827846, "averageVolume10days": 1321310, "averageDailyVolume10Day": 1321310, "bid": 6.66, "ask": 6.67, "bidSize": 800, "askSize": 800, "marketCap": 1151505024, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 6.94, "priceToSalesTrailing12Months": 153.82114, "fiftyDayAverage": 3.9564, "twoHundredDayAverage": 2.88155, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 188061040, "profitMargins": 0.0, "floatShares": 56217025, "sharesOutstanding": 173680992, "sharesShort": 1415962, "sharesShortPriorMonth": 1366756, "sharesShortPreviousMonthDate": 1693440000, "dateShortInterest": 1695945600, "sharesPercentSharesOut": 0.0082, "heldPercentInsiders": 0.08449, "heldPercentInstitutions": 0.81597, "shortRatio": 4.82, "shortPercentOfFloat": 0.0175, "impliedSharesOutstanding": 173680992, "bookValue": 1.32, "priceToBook": 5.022727, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": -155082000, "trailingEps": -1.19, "forwardEps": -0.87, "enterpriseToRevenue": 25.122, "enterpriseToEbitda": -1.178, "52WeekChange": 2.6333334, "SandP52WeekChange": 0.26208627, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.63, "targetHighPrice": 12.0, "targetLowPrice": 4.8, "targetMeanPrice": 8.88, "targetMedianPrice": 9.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 307500000, "totalCashPerShare": 1.77, "ebitda": -159684000, "totalDebt": 50938000, "quickRatio": 8.419, "currentRatio": 8.654, "totalRevenue": 7486000, "debtToEquity": 22.211, "revenuePerShare": 0.055, "returnOnAssets": -0.27201, "returnOnEquity": -0.69878995, "grossProfits": -130860000, "freeCashflow": -112359624, "operatingCashflow": -127036000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -22.23698, "financialCurrency": "USD", "trailingPegRatio": null}]